Semaglutide's Nonarteritic Anterior Ischemic Optic Neuropathy Risk Systematically Assessed in Multiple Reviews.
Re: Liu et al.: Rate and risk of nonarteritic anterior ischemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis (Ophthalmology 2026;133;589-598).
Abstract
Multiple systematic reviews and meta-analyses investigate the rate and risk of nonarteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide use for diabetes and weight loss.